X

Cytokinetics, Incorporated (CYTK) Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated (NASDAQ: CYTK) FY 2026 Other Release

Newsdesk: